New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
16:14 EDTEXASExact Sciences initiated with a Buy at Mizuho
Target $13.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information
June 22, 2015
07:53 EDTEXASExact Sciences estimates raised ahead of analyst Day at Canaccord
Canaccord raised its estimates on Exact Sciences ahead of June 26 Analyst Day. The firm cited the impact from the 160-person sales force addition from Ironwood Pharmaceuticals and pipeline opportunities beyond Cologuard for the increase. Canaccord raised its price target to $32 from $30 on Exact Sciences shares.
June 19, 2015
08:40 EDTEXASJefferies sees significant upside for Exact Sciences on positive USPSTF review
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use